Triple Analysis: Prostate Cancer, Antibodies and Peptides

BioSeeker Group AB
January 7, 2013
4867 Pages - SKU: BIOS4940035
This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two compound strategies of Antibodies and Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part II: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:
  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.



More Oncology/Hematology reports by BioSeeker Group AB

Wnt Signaling Pathway in Oncology Drug Pipeline Update 2014 by BioSeeker Group AB
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2014Abnormalities in the Wnt signaling pathway are associated with a large variety of human malignancies including tumors ...
Viral Carcinogenesis Drug Pipeline Update 2014 by BioSeeker Group AB
Viral Carcinogenesis Drug Pipeline Update 2014There is a strong association between viruses and the development of human malignancies. We now know that at least six ...
VEGF Signaling Pathway in Cancer Drug Pipeline Update 2014 by BioSeeker Group AB
VEGF Signaling Pathway in Cancer Drug Pipeline Update 2014There is now much evidence that VEGFR-2 is the major mediator of VEGF-driven responses in endothelial cells ...
TSLP Signaling Pathway in Oncology Drug Pipeline Update 2014 by BioSeeker Group AB
TSLP Signaling Pathway in Oncology Drug Pipeline Update 2014Thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine that play various roles in a broad spectrum of ...
See all reports like this >>

 

SELECT A LICENSE

    Electronic Access
Single User Fulfilled by Publisher
  USD 5,175  
    Electronic Access
Global Site License Fulfilled By Publisher
  USD 12,937.50  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!